Skip to content

Anxiety around eating or body image emerging during GLP-1 treatment

For some people, GLP-1 treatment brings up new or returning anxiety about food and body image, even without a prior diagnosis. What the evidence shows, how to recognize it, and what to do.

Updated Sep 26, 2026Evidence-backed

GLP-1 medications change your relationship with food quickly, and for most people that feels like relief. For some, the same fast change brings up new anxiety about eating or about a changing body, even with no prior history. This guide covers what the research shows and what to look out for.

Why this can happen without a prior history

On a GLP-1, appetite, food noise, and satiety can all shift within weeks. Most people welcome it. For some, the speed of the change stirs up anxiety: about eating enough, about losing "too much" control over food, or about a changing body that brings up unexpected feelings. That can happen in people with no prior diagnosed eating disorder or body dysmorphia.

What the evidence shows

The research is reassuring for groups of people while still leaving room for individual experience, so it helps to look at the two separately.

At the group level, studies haven't found worsening. A cohort of 666 adults with Class 3 obesity in a multidisciplinary weight-management program compared validated eating-disorder and psychological-distress measures (EDE-QS, K10, DASS-21) between people on a GLP-1 and people not on one, and found no significant differences. Among 31 participants who started a GLP-1 during the study, none of those scores changed significantly over 12 months despite substantial weight loss, and none stopped the medication because of eating-disorder symptoms or distress (Maynard et al., International Journal of Eating Disorders, 2025, DOI (external link)). A separate large claims-based analysis using a target-trial-emulation design found no increased risk of eating disorders, depression, or stress-related disorders among GLP-1 initiators, and lower risks of anxiety and insomnia (Hussain et al., Diabetes, Obesity & Metabolism, 2026, DOI (external link)). That cohort was specifically people with opioid use disorder, which limits how far it applies to others.

For individuals, case reports show it can happen. Published cases describe restrictive eating starting or getting worse during semaglutide use, including in an adolescent (Liekens et al., BJPsych Open, 2025, DOI (external link)) and in the context of atypical anorexia nervosa (Guerdjikova et al., Journal of Clinical Psychopharmacology, 2024, DOI (external link)). Case reports show that something occurs. They can't show how often.

Taken together, there's no good evidence that GLP-1 treatment raises eating-disorder risk across the board, and reasonable evidence that on average it doesn't. That's reassuring, but it isn't a guarantee about you. If your own experience is heading somewhere difficult, group averages don't cancel that out, and the signs below still deserve action.

Signs to pay attention to

  • Feeling anxious or guilty about eating, even when you're eating normally
  • A growing preoccupation with weight-loss numbers, beyond what feels healthy or beyond your original goal
  • Avoiding food or under-eating more than appetite suppression alone would explain
  • Checking your body, weight, or appearance much more often than before treatment
  • Feeling distressed on days when your appetite is stronger or you eat more than usual
  • A sense that your relationship with food has become more anxious or rigid, not just different

Why it's easy to miss

Some drop in food preoccupation is an expected, helpful effect of these medications (see our guide on suppression, satiation, and satiety), so it can be hard to tell "the medication is working" from "something more concerning is developing." A rough test: if your relationship with food feels quieter, that fits the medication working. If it feels more anxious or rigid, pay attention.

What to do

Raise it early instead of waiting for it to pass. Talk to your prescriber (see also mood changes and anhedonia), and ideally to a mental health provider experienced with eating-related concerns. Our discussion guide on talking to a mental health provider about body image or disordered eating history shows how to start that conversation, even if you have no prior diagnosis. If you have a current or past eating disorder, our guide on GLP-1s and a history of disordered eating covers that decision in more depth.

Study findings above are attributed to their authors and were located via PubMed.

This is general education, not medical advice. New or worsening anxiety around food or your body is worth raising with your prescriber or a mental health professional.

anxietybody-imagedisordered-eatingside-effectsmental-health

Was this helpful?

Common questions

Questions people often ask about this topic.

  • Do GLP-1 medications worsen eating disorders or eating-related anxiety?

    Studies that looked at groups of people haven't found worsening. A cohort of 666 adults with Class 3 obesity found no significant differences in validated eating-disorder and distress measures between GLP-1 users and non-users, and among those who started treatment, no significant change over 12 months despite substantial weight loss; none stopped because of eating-disorder symptoms. A large claims-based analysis in people with opioid use disorder likewise found no increased risk of eating disorders, depression, or stress-related disorders. That's reassuring at the group level, but it isn't a guarantee about any one person.

  • Can a GLP-1 cause anxiety about food even if I've never had an eating disorder?

    For some people, yes. GLP-1 medications change appetite, food noise, and satiety quickly. Most people experience that as relief, but the speed of the change can bring up new anxiety about eating enough, losing control over food, or a changing body, even without a prior diagnosed eating disorder or body dysmorphia. Published case reports describe restrictive eating starting or getting worse during treatment. They show it happens but not how often, and group-level studies haven't found an overall increase.

  • How do I tell the difference between the medication working and something more concerning developing?

    A rough test: if your relationship with food feels quieter, that fits the medication working as intended. If it feels more anxious or rigid, pay attention. Less food preoccupation is expected; growing guilt, fixation on numbers, or distress on higher-appetite days is not just "part of the process."

  • What signs around eating or body image should I watch for on a GLP-1?

    Watch for anxiety or guilt about eating normally, a growing preoccupation with weight-loss numbers beyond your original goal, under-eating more than appetite suppression alone would explain, checking your body or weight much more often than before, and distress on days when you eat more than usual.

  • What should I do if I notice new anxiety around food or my body during treatment?

    Raise it early instead of waiting for it to pass: with your prescriber, and ideally with a mental health provider experienced with eating-related concerns. Group averages don't cancel out your own experience. If yours is heading somewhere difficult, name it and get support, even without a prior diagnosis.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

2Supporting

2Challenging

  • Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity (external link)

    International Journal of Eating Disorders, 2025 · Peer-reviewed study · Moderate evidence

    Maynard S, Hay P, Chimoriya R, et al. (2025) · Int J Eat Disord

    doi:10.1002/eat.24575

    Retrospective cohort of 666 adults with Class 3 obesity using validated instruments (EDE-QS, K10, DASS-21): no significant differences between GLP-1 users and non-users at baseline, and among 31 people who initiated treatment, no significant change in eating-disorder risk or psychological distress over 12 months despite substantial weight loss. None discontinued due to ED symptoms. The strongest direct counterweight to the case-report literature, and the reason this article now leads with group-level reassurance. Observational, single-program, and small initiator subgroup.

  • Association of GLP-1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation (external link)

    Diabetes, Obesity & Metabolism, 2026 · Peer-reviewed study · Moderate evidence

    Hussain T, Al Faysal J, Kotecha P, et al. (2026) · Diabetes Obes Metab

    doi:10.1111/dom.70867

    Claims-based target trial emulation with time-conditional propensity score matching: no increased risk of eating disorders, depression, stress-related disorders, or suicidal behaviour among GLP-1 initiators, and lower risks of anxiety (aHR 0.76) and insomnia (0.78). Supports the group-level finding. Important limitation stated in the article: the cohort is specifically people with opioid use disorder, so generalization is limited; residual confounding cannot be excluded.

1Mixed findings

Revision history

Last updated · 3 revisions recorded.

Show what changed
  1. v3

    Common questions revised

  2. v2

    Summary rewritten; Body revised

  3. v1

    Existing article recorded at the start of version history

Improve this page

Community notes

Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.

Loading notes…

    New submissions are currently paused. Existing approved notes remain available.

    Related terms

    • Pharmacovigilance — The science and practice of detecting, assessing, and preventing adverse effects of medications once they are in real-world use, after clinical trials end.
    • Telogen effluvium — A temporary form of diffuse hair shedding that begins two to three months after a physical stressor — including rapid weight loss — pushes many hair follicles into their resting phase at once.
    • FAERS (FDA Adverse Event Reporting System, now AEMS) — The FDA's database of voluntary side-effect reports from patients, clinicians, and manufacturers, used to detect safety signals after a drug is on the market. In March 2026 it became part of the FDA Adverse Event Monitoring System (AEMS).
    • Lowest effective dose — The smallest dose of a medication that produces the intended benefit with tolerable side effects. It is a standard prescribing principle.

    Related guides